WO2022127946A1 - Uso de composiciones vacunales basadas en el dominio de unión al receptor del virus sars-cov-2 en el desarrollo de una inmunidad protectora - Google Patents
Uso de composiciones vacunales basadas en el dominio de unión al receptor del virus sars-cov-2 en el desarrollo de una inmunidad protectora Download PDFInfo
- Publication number
- WO2022127946A1 WO2022127946A1 PCT/CU2021/050014 CU2021050014W WO2022127946A1 WO 2022127946 A1 WO2022127946 A1 WO 2022127946A1 CU 2021050014 W CU2021050014 W CU 2021050014W WO 2022127946 A1 WO2022127946 A1 WO 2022127946A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rbd
- sars
- cov
- use according
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000001681 protective effect Effects 0.000 title claims abstract description 14
- 230000036039 immunity Effects 0.000 title claims abstract description 13
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 title 1
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 29
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 22
- 102000005962 receptors Human genes 0.000 claims abstract description 12
- 108020003175 receptors Proteins 0.000 claims abstract description 12
- 230000000091 immunopotentiator Effects 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 6
- 102000036639 antigens Human genes 0.000 claims abstract description 6
- 108091007433 antigens Proteins 0.000 claims abstract description 6
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract description 6
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 5
- 229960003983 diphtheria toxoid Drugs 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims abstract description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 22
- 241000700605 Viruses Species 0.000 claims description 19
- 230000003053 immunization Effects 0.000 claims description 19
- 238000002649 immunization Methods 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 230000006916 protein interaction Effects 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 230000004727 humoral immunity Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 102000018265 Virus Receptors Human genes 0.000 claims description 2
- 108010066342 Virus Receptors Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 229940031626 subunit vaccine Drugs 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 238000002255 vaccination Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 108700021021 mRNA Vaccine Proteins 0.000 description 4
- 229940126582 mRNA vaccine Drugs 0.000 description 4
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention is related to Biotechnology and Medicine. Particularly, with the use of vaccine compositions based on the Receptor Binding Domain of the SARS-COV-2 virus in the treatment of patients recovered from COVID19 and in those vaccinated subjects where protective immunity does not develop, in which it has decreased or no significant natural protective antibody response was induced.
- the COVID19 disease is of very recent appearance, in Wuhan, China in December 2019, where serious cases of pneumonia of unknown etiology began to be reported.
- the disease caused by the SARS-CoV-2 virus is characterized by rapid spread between people, mainly with the appearance of symptoms such as fever, cough, runny nose, sore throat and difficulty breathing, in symptomatic cases, which represent less than fifty %.
- the disease is asymptomatic, this being an important element in the spread of the disease and an epidemiological challenge for its control (WHO Coronavirus disease (COVID-2019) situation reports. https://www.who .int/emergencies/diseases/novel-coronavirus 2019/situation-reports (Accessed 13 August 2020).
- SARS-CoV-2-like coronaviruses known as MERS and SARS
- MERS and SARS have been causative agents of similar epidemics in previous decades.
- SARS has greater homology with SARS-CoV-2, and one of the elements of similarity is that both viruses use the ACE2 protein as a receptor to penetrate human cells. Therefore, in SARS as in SARS-CoV-2, the interaction between the receptor binding domain (RBD) of the viral protein S1 and the ACE2 protein (angiotensin-converting enzyme 2 ) is decisive for infection with the virus in humans.
- RBD receptor binding domain
- This RBD domain of the S protein or also known as the Spike of the SARS-CoV-2 virus is a fragment of approximately 195 amino acids (corresponding to the sequence 333-527) that contains the receptor binding motif (RBM). motive) that constitutes the region through which the virus interacts with the ACE2 receptor.
- RBM receptor binding motif
- the RBD It also contains 4 intramolecular bisulfide bridges between Cisternae 336-361, 379-432, 391-525 and 480-488, respectively, which generates a very compact and stable structure (Lan and cois (2020), Nature https://doi .Org/10.1038/s41586-020-2180-5).
- the RBD is a small molecule, whose molecular mass ranges between 25-27 kDa depending on the host where it is expressed and the carbohydrates incorporated, mainly in the asparagines N331 and N343 (Chen, WH et al (2017) Journal of Pharmaceutical Sciences 106: 1961 -1970).
- Vaccine strategies have gone from using the inactivated virus, through genetic constructions that contain the genetic material of the virus incorporated either in adenovirus or as messenger RNA, to subunit vaccines obtained by molecular biology in hosts.
- the preferred molecules for this purpose are the S protein, or a fragment of its structure: the RBD.
- the present invention describes for the first time, the use of vaccine compositions based on the receptor binding domain of the SARS-CoV-2 virus, in the treatment of patients recovered from COVID19 in whom there has been a decrease or no induced significant natural protective antibody response. Additionally, they can be used in individuals previously vaccinated with an adenovirus or RNA-type vaccine technology.
- the vaccine compositions described are also being tested in uninfected individuals, but now show for the first time their ability to efficiently re-stimulate a strong immune response with neutralizing capacity in convalescent patients.
- both vaccine strategies are based on a small recombinant protein of the SARS-CoV-2 virus, the RBD, may give particular advantages in this field of application.
- a highly targeted response against the RBM which determines the natural interaction of the virus with the ACE2 receptor on host cells, is amplified/potentiated.
- This protective response is an advantage when compared to other vaccine strategies such as attenuated virus vaccines, those based on the entire S protein or those based on viral vectors.
- the present invention relates to the use of vaccine compositions that comprise the receptor binding domain (RBD) of the SARS-CoV-2 virus in the treatment of patients recovered from COVID19.
- said recovered patients have humoral immunity characterized by at least one of the following conditions: response titer against RBD less than 1/1000, inhibition capacity of the RBD-ACE2 protein interaction less than 50% in a 1/100 dilution or SARS-CoV-2 neutralizing antibody titer below 1/160.
- the present invention relates to the aforementioned use of vaccine compositions characterized in that they comprise a covalent conjugate between RBD and a carrier protein selected from the group comprising: tetanus toxoid, diphtheria toxoid and CRM197 .
- Other vaccine compositions used in the use claimed in the present invention are those that comprise RBD as antigen, either in the form of monomer or dimer absorbed in AIOH 3 .
- Other claimed vaccine compositions include the use of immunopotentiators such as the outer membrane vesicle of Neisseria meningitidis.
- the above vaccine compositions are administered to patients recovered from COVID-19 in an intramuscular or subcutaneous immunization scheme that comprises a dose range between 1-100 pg of RBD, in a range of 1 to 3 immunizations, at intervals between 21 to 28 days.
- the object of the present invention is the use according to the previous immunization scheme to obtain hyperimmune plasma with a high neutralizing capacity for SARS-CoV-2.
- the present invention contemplates the use of the vaccine compositions referred to herein, in the immunization of subjects vaccinated with vaccine platforms other than subunit vaccines and who have not developed effective protective immunity or when it has decreased over time and It is not recommended to give a booster dose with the same vaccine used in primary immunization, as is the case with Adenovirus, inactivated Virus, attenuated Virus and mRNA vaccines.
- An effective protective immunity according to the present invention is when at least one of the following conditions are met: response titer against RBD greater than 1/1000, inhibition capacity of the RBD-ACE2 protein interaction greater than 50% in a 1 dilution /100 or SARS-CoV-2 neutralizing antibody titer above 1/160.
- the present invention describes the use of vaccine compositions based on the receptor-binding domain of the SARS-CoV-2 virus in recovered (convalescent) patients from COVID19, in whom there are no longer significant levels of natural anti-RBD antibodies that confer capacity neutralizing.
- these vaccine compositions may contain dimeric and/or monomeric forms of the RBD absorbed in AIOH 3 , with or without an immunopotentiator, or be more complex, such as those described in detail in patent applications CU-2020-0057 and CU-2020-0057. 2020-0069, without being limited to these.
- anti-RBD antibody titer below 1/1000 measured by ELISA, or neutralizing antibody titer of SARS affectivity -CoV-2 less than 1/160 measured by assays using the live virus or a pseudo virus, or inhibition capacity of the molecular interaction between the RBD and the ACE2 protein less than 50% at a serum dilution of 1/100 measured by a competitive ELISA.
- the vaccine preparations induce the activation of the memory immune response against the virus, guaranteeing the existence of high titers of RBD antibodies, mostly with neutralizing capacity for several months (at least 6 months).
- an additional booster dose may be administered to restore protection.
- the vaccine compositions referred to in of the present invention can be used in the immunization of subjects vaccinated with vaccine platforms other than subunit vaccines that have not developed effective protective immunity or once immunity declines and a booster dose is required. It is reported in the literature that with vaccine platforms based on adenovirus vectors, subjects can only be immunized between 1-2 times, because after the first injection the organism produces antibodies against the adenoviral vector itself that can make the second dose ineffective. . (Casimiro, DR et al. (2003) J. Virol., 77: 7663-7668).
- the vaccine preparations are administered to convalescent patients in an intramuscular or subcutaneous immunization scheme that includes a dose range between 1-100 pg of RBD, preferably between 30-60 pg, in a range of 1 to 3 immunizations, at regular intervals. between 21 -28 days.
- the present invention also contemplates a method for obtaining hyperimmune plasma with neutralizing capacity for the SARS-CoV-2 virus, with the antibodies produced by convalescent patients from COVID19 after vaccination.
- Hyperimmune plasma is useful for the treatment of moderate, severe or critical COVID19 patients, as has been shown by multiple authors (Bloch EM et al. (2020) J Clin Invest. 130:2757-65, Casadevall A. (2020) JAMA 324:455-7).
- donors must be symptom-free, negative for SARS-CoV-2 detection by real-time PCR, and have a neutralizing antibody titer of at least 1/160, according to recommendations. from the EDA (US Department of Health and Human Services Food and Drug Administration.
- Figure 2 Percentage values of inhibition of the RBD-ACE2 interaction of sera from subjects six months after receiving immunization scheme with mRNA vaccine and after applying booster dose with RBD vaccine.
- B Concentration of anti-RBD antibodies detected in subjects immunized with inactivated virus vaccine who received booster doses with RBD vaccine.
- Example 1 Variability of anti-RBD titers and inhibitory capacity of the RBD-ACE2 interaction in Cuban patients recovered from COVID19.
- NUNC Maxisorp 96-well microtiter plates were coated with 50 pL of RBD at a concentration of 5 pg/mL in phosphate-buffered saline (PBSS) pH 7.0, incubated for 1 hour at 37°C , and at the end the assays were blocked. uncoated sites using 150 pL of a blocking solution (SSTF, Tween 20 (0.05%) [v:v] and 4% skimmed milk) for 30 minutes at 37 ° C. Then the sera dissolved in solution were added.
- PBSS phosphate-buffered saline
- Sera from these same 39 convalescents were used in an ELISA to determine their ability to inhibit the interaction of RBD and ACE2.
- the plates coated with human ACE2-Fc (5 pg/mL) were blocked and the mouse RBD-Fc mixture with serum from convalescent individuals was added to them. dilutions from 1:100 to 1:10,000, which had been previously incubated for 1 h at 37 ° C.
- 41% had inhibition values less than 30% and anti-RBD antibody titers less than 1/800.
- the correlation was analyzed by the Spearman correlation method
- both patients were immunized with 50 pg of dimeric RBD absorbed in AIOH3 and after 14 days of the immunization blood was drawn and with the serum obtained, the anti-RBD antibody titer and inhibition capacity of the RBD-ACE2 protein interaction and SARS-CoV-2 neutralizing antibody titer were determined again.
- Table 1 shows the results of the two patients for the determinations made at time 0 (before immunization) and 14 days after immunization. As can be seen, both patients showed high titers of anti-RBD antibodies after a single immunization, values of inhibition of RBD-ACE2 protein interaction greater than 80%, and neutralizing antibody titers much higher than 1/160. It is important to note that the neutralizing titers increase to a greater extent than the anti-RBD titers, which supports that the applied immunization preferentially enriches the serum/plasma in antibodies with neutralizing capacity.
- Example 3 Increase in the concentration of anti-RBD antibodies and inhibitory capacity of the RBD-ACE2 interaction in subjects previously immunized with inactivated vaccine and mRNA receiving booster doses with a vaccine composition comprising RBD.
- FIG. 2 shows the inhibitory capacity of sera from individuals vaccinated with mRNA vaccine and given a booster dose of a vaccine composition containing the outer membrane vesicle RBD of Neisseria meningitidis adsorbed on AIOH3 (Fig. 2A).
- the inhibition values are below 65%, and after immunization with the booster dose, these values increase above 90% for all subjects. evaluated.
- Example 4 Increase in the concentration of anti-RBD antibodies in subjects previously immunized with the RBD vaccine, receiving booster doses with a vaccine composition comprising RBD conjugated to tetanus toxoid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3202603A CA3202603A1 (en) | 2020-12-16 | 2021-12-14 | Use of vaccine compositions based on sars-cov-2 receptor binding domain in delivering protective immunity |
KR1020237024030A KR20240035738A (ko) | 2020-12-16 | 2021-12-14 | Sars-cov-2 수용체 결합 도메인을 기반으로 한 백신 조성물의 보호 면역 전달 용도 |
CN202180093131.7A CN117440825A (zh) | 2020-12-16 | 2021-12-14 | 基于SARS-CoV-2病毒的受体结合结构域的疫苗组合物在保护性免疫的发展中的用途 |
EP21854867.5A EP4265272A1 (en) | 2020-12-16 | 2021-12-14 | Use of vaccine compositions based on sars-cov-2 receptor binding domain in delivering protective immunity |
AU2021404744A AU2021404744A1 (en) | 2020-12-16 | 2021-12-14 | Use of vaccine compositions based on sars-cov-2 receptor binding domain in delivering protective immunity |
US18/266,486 US20240042013A1 (en) | 2020-12-16 | 2021-12-14 | Use of vaccine compositions based on sars-cov-2 receptor binding domain in delivering protective immunity |
JP2023536891A JP2024510065A (ja) | 2020-12-16 | 2021-12-14 | 防御免疫の送達における、sars-cov-2受容体結合ドメインに基づくワクチン組成物の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020-0101 | 2020-12-16 | ||
CU20200101 | 2020-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022127946A1 true WO2022127946A1 (es) | 2022-06-23 |
Family
ID=80445721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2021/050014 WO2022127946A1 (es) | 2020-12-16 | 2021-12-14 | Uso de composiciones vacunales basadas en el dominio de unión al receptor del virus sars-cov-2 en el desarrollo de una inmunidad protectora |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240042013A1 (es) |
EP (1) | EP4265272A1 (es) |
JP (1) | JP2024510065A (es) |
KR (1) | KR20240035738A (es) |
CN (1) | CN117440825A (es) |
AU (1) | AU2021404744A1 (es) |
CA (1) | CA3202603A1 (es) |
CL (1) | CL2023001722A1 (es) |
WO (1) | WO2022127946A1 (es) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021207599A1 (en) * | 2020-04-10 | 2021-10-14 | Akston Biosciences Corporation | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
WO2021207281A2 (en) * | 2020-04-06 | 2021-10-14 | Eisai R&D Management Co., Ltd. | Vaccines, adjuvants, and methods of generating an immune response |
WO2022013324A2 (en) * | 2020-07-14 | 2022-01-20 | Riboxx Gmbh | Post-exposure vaccination against viral respiratory infections |
-
2021
- 2021-12-14 WO PCT/CU2021/050014 patent/WO2022127946A1/es active Application Filing
- 2021-12-14 US US18/266,486 patent/US20240042013A1/en active Pending
- 2021-12-14 CN CN202180093131.7A patent/CN117440825A/zh active Pending
- 2021-12-14 KR KR1020237024030A patent/KR20240035738A/ko unknown
- 2021-12-14 JP JP2023536891A patent/JP2024510065A/ja active Pending
- 2021-12-14 CA CA3202603A patent/CA3202603A1/en active Pending
- 2021-12-14 AU AU2021404744A patent/AU2021404744A1/en active Pending
- 2021-12-14 EP EP21854867.5A patent/EP4265272A1/en active Pending
-
2023
- 2023-06-14 CL CL2023001722A patent/CL2023001722A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021207281A2 (en) * | 2020-04-06 | 2021-10-14 | Eisai R&D Management Co., Ltd. | Vaccines, adjuvants, and methods of generating an immune response |
WO2021207599A1 (en) * | 2020-04-10 | 2021-10-14 | Akston Biosciences Corporation | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
WO2022013324A2 (en) * | 2020-07-14 | 2022-01-20 | Riboxx Gmbh | Post-exposure vaccination against viral respiratory infections |
Non-Patent Citations (27)
Title |
---|
BLOCH EM, J CLIN INVEST, vol. 130, 2020, pages 2757 - 65 |
BOSNJAK, B, CELL MOL IMMUNOL. DOI: 10.1 038/S41423-020-00573-9, 2020 |
CASADEVALL A., JAMA, vol. 324, 2020, pages 455 - 7 |
CASIMIRO, DR, J. VIROL., vol. 77, 2003, pages 7663 - 7668 |
CHANG-MONTEAGUDO: "A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial", THE LANCET REGIONAL HEALTH -AMERICAS, 15 September 2021 (2021-09-15), pages 79, XP055909692, Retrieved from the Internet <URL:https://reader.elsevier.com/reader/sd/pii/S2667193X21000752?token=E96BE4CF4807CDCDC5D0A26A9A0CEA541A663D7C465560DCFB77F4E4EFD6E4F0AD8AD7C43893133328810830127BE521&originRegion=eu-west-1&originCreation=20220408120614> [retrieved on 20220406], DOI: 10.1016/j.lana.2021.10 * |
CHEN, WH, JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 106, 2017, pages 1961 - 1970 |
DE LA RICA, RBORGES MGONZALEZ-FREIRE, M, FRONT. IMMUNOL., 2020, Retrieved from the Internet <URL:https://doi.org/10.3389/fimmu.2020.558898> |
HANSEN JOHANNA ET AL: "Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail", SCIENCE, vol. 369, no. 6506, 21 August 2020 (2020-08-21), US, pages 1010 - 1014, XP055864281, ISSN: 0036-8075, Retrieved from the Internet <URL:https://www.science.org/doi/pdf/10.1126/science.abd0827?casa_token=nwcFDFSirxYAAAAA:gLprG5E4PhWD6flS0vrfFIRROvQu66E4Xx4ulVRklCrg7GxswfkjRmyrFpVLzNN3xZ6o-Sqlg2LAnQ> DOI: 10.1126/science.abd0827 * |
KRAMMER FLORIAN: "SARS-CoV-2 vaccines in development", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 586, no. 7830, 23 September 2020 (2020-09-23), pages 516 - 527, XP037277122, ISSN: 0028-0836, [retrieved on 20200923], DOI: 10.1038/S41586-020-2798-3 * |
LAN L, JAM, vol. 323, 2020, pages 1502 - 3 |
LEE, W, THE JOURNAL OF INFECTIOUS DISEASES, DOI: 10.1093/INFDIS/JIAA673, 2020 |
LOGUNOV DENIS Y ET AL: "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 396, no. 10255, 4 September 2020 (2020-09-04), pages 887 - 897, XP086269562, ISSN: 0140-6736, [retrieved on 20200904], DOI: 10.1016/S0140-6736(20)31866-3 * |
MARTÍNEZ, ANALES DE LA ACADEMIA DE CIENCIAS DE CUBA, vol. 10, no. 2, 2020, Retrieved from the Internet <URL:http://wwv.rovistaccuba.sld.cu> |
MIRZAEI RASOUL ET AL: "Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 88, 24 August 2020 (2020-08-24), XP086319656, ISSN: 1567-5769, [retrieved on 20200824], DOI: 10.1016/J.INTIMP.2020.106928 * |
OVERBAUGH, J, NATURE, vol. 584, no. 7821, 2020, pages 1678 - 1685 |
POLLET JEROEN ET AL: "SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice", BIORXIV : THE PREPRINT SERVER FOR BIOLOGY, 5 November 2020 (2020-11-05), United States, XP055824766, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.11.04.367359v2.full.pdf> [retrieved on 20210715], DOI: 10.1101/2020.11.04.367359 * |
QU, YMCONG HY, TRAVEL MED INFECT DIS, vol. 34, 2020, pages 101619 |
RIVA, CRITICAL CARE, vol. 24, 2020, pages 549 |
SALAZAR, E, BIORXIV, 2020, Retrieved from the Internet <URL:https://doi.org/10.1101/2020.06.08.138990> |
SEOW JEFFREY ET AL: "Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans", NATURE MICROBIOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 5, no. 12, 26 October 2020 (2020-10-26), pages 1598 - 1607, XP037298617, DOI: 10.1038/S41564-020-00813-8 * |
SEOW, J, NATURE MICROBIOLOGY DOI: 10.1038/S41564-020-00813-8, 2020 |
TAN, C, NATURE BIOTECHNOLOGY, 2020, Retrieved from the Internet <URL:https://doi.org/10.1038/s41587-020-0631-z> |
TILLETT, R, LANCET INFECT DIS, 2020, Retrieved from the Internet <URL:https://doi.org/10.1016/S1473-3099(20)30764-7> |
TISONCIK, J, MICROBIOLOGY AND MOLECULAR BIOLOGY, vol. 76, no. 1, 2012, pages 16 - 32 |
WALLS A, CELL, vol. 180, 2020, pages 281 - 292 |
XU, X, MILITARY MEDICAL RESEARCH, vol. 7, 2020, pages 22 |
YANG JINGYUN ET AL: "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity", NATURE, vol. 586, no. 7830, 29 July 2020 (2020-07-29), pages 572 - 577, XP037341143, ISSN: 0028-0836, DOI: 10.1038/S41586-020-2599-8 * |
Also Published As
Publication number | Publication date |
---|---|
EP4265272A1 (en) | 2023-10-25 |
US20240042013A1 (en) | 2024-02-08 |
CN117440825A (zh) | 2024-01-23 |
AU2021404744A1 (en) | 2023-07-06 |
JP2024510065A (ja) | 2024-03-06 |
CL2023001722A1 (es) | 2024-01-26 |
KR20240035738A (ko) | 2024-03-18 |
CA3202603A1 (en) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bakhiet et al. | SARS-CoV-2: Targeted managements and vaccine development | |
Blumberg et al. | The immunogenicity of influenza virus vaccine in solid organ transplant recipients | |
Trifonova et al. | Study of rubella candidate vaccine based on a structurally modified plant virus | |
US7943147B2 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
Aygün et al. | Coronavirus infections in childhood and vaccine studies | |
Pavel et al. | Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model | |
TW202202169A (zh) | 預防嚴重急性呼吸症候群冠狀病毒第二型(sars-cov-2)感染的生物可降解奈米複合物疫苗及方法 | |
Ismail et al. | COVID-19 in children: Could pertussis vaccine play the protective role? | |
Cox et al. | Non‐lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication | |
Marta et al. | COVID-19 vaccines: Update of the vaccines in use and under development | |
Mahallawi et al. | Infection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue | |
Kasel et al. | Human influenza: aspects of the immune response to vaccination | |
WO2022127946A1 (es) | Uso de composiciones vacunales basadas en el dominio de unión al receptor del virus sars-cov-2 en el desarrollo de una inmunidad protectora | |
JP2007505836A (ja) | 麻疹サブユニットワクチン | |
Deshpande et al. | MMR vaccine and COVID-19: a myth or a low risk-high reward preventive measure? | |
KR20200053644A (ko) | 보강제 제형 및 방법 | |
BR112020001586A2 (pt) | vacina contra malária | |
ES2557315T3 (es) | Nuevo virus de la gripe | |
Bissett et al. | Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine | |
Young et al. | Immunologic characterization of a novel inactivated nasal mumps virus vaccine adjuvanted with Protollin | |
Yaqinuddin et al. | Advantageous non-specific effects of live-attenuated vaccines in COVID-19 treatment. | |
Frieman et al. | Enhancing the Protection of Influenza Virus Vaccines with BECC TLR4 Adjuvant in Aged Mice | |
Johnson et al. | Recombinant vaccinia immunization in the presence of passively administered antibody | |
Burgess et al. | 2751. Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED): Methods | |
Han et al. | 2750. Sequential Influenza A H1N1 and Influenza A H3N2 Challenge Infections in Healthy Volunteers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21854867 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023536891 Country of ref document: JP Ref document number: MX/A/2023/007165 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 3202603 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023011896 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021404744 Country of ref document: AU Date of ref document: 20211214 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023011896 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230615 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021854867 Country of ref document: EP Effective date: 20230717 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180093131.7 Country of ref document: CN |